Manufacturing Devices In The Rollercoaster UK Market

A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare and longstanding medical device CDMO Renfrew Group International give their take on the environment for manufacturers and the opportunities for strengthening the industry base.

Rollercoaster
• Source: Shutterstock

A new report issued in fall 2023 by research organization CPI is the latest initiative to highlight the need for better long-term support for medtech industry manufacturing. It proposes a strategy for scale-up.

More from Manufacturing Focus

Q&A: Rentschler’s CEO On The CDMO’s Pivot Away From Cell And Gene Therapy And More

 
• By 

Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.

CCRM: Building A Global Regenerative Medicine Ecosystem From Canadian Roots

 
• By 

The Centre for Commercialization of Regenerative Medicine has spent over a decade crafting a cell and gene therapy ecosystem in Canada. Now it is replicating the model abroad.

Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm

 
• By 

Artiva Biotherapeutics is hoping its NK cell therapy approach, which uses un-engineered cells, will prove effective in both oncologic and autoimmune indications and safe enough to be given in the community setting.

New Manufacturing Technologies Are Here – What's Stopping Their Implementation?

 

Pharmaceutical manufacturing is developing at a lightning pace as the confluence of automation and AI creates opportunities for much higher efficiency and throughput. Experts from across the industry discuss these, and the challenges around implementation and standardization.

More from In Vivo

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By 

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Deals In Depth: February 2025

 
• By 

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth

 
• By 

From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.